Digital Health Startup Funding 2025-2026

What are all the funding deals in the digital health market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play digital health companies between August 2025 and July 2026. We count as “pure-play” digital health companies those using digital technology to deliver, support, or improve healthcare and health outcomes.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how digital health fits inside healthcare delivery and clinical operations, we cover it in our Digital Health market report.

How active has fundraising been in the digital health market?

As of July 2026, fundraising in the digital health market has been active but selective. Over the past 12 months, pure-play digital health companies raised 44 disclosed equity rounds and $1.71B in combined capital.

That equals an average of 3.67 deals per month, with a median of 3.5 deals per month. In plain terms, the digital health market kept producing deal flow, but not at a frantic pace.

Monthly dollar flow was much less stable than monthly deal flow. The average month produced $142.7M, while the median month produced $100.2M, which shows that a few larger months lifted the average.

June 2026 was the strongest month, with 9 deals and $400.9M raised. November 2025 had no qualifying public rounds, which is a reminder that digital health funding is still lumpy month to month.

If you want to go deeper on the companies behind this activity, see our market report covering digital health startups.

How concentrated has fundraising been in the digital health market?

As of July 2026, fundraising in the digital health market was meaningfully concentrated, but not dependent on one single company. Over the past 12 months, the top deal represented 11.7% of all disclosed capital.

The top 3 deals represented 27.5% of total capital, while the top 5 represented 39.1%. By the time we reach the top 10, those deals absorb 58.3% of all disclosed funding.

This means market totals should be read carefully. A headline number of $1.71B sounds broad, but more than half of that came from just 10 companies.

The market is not as concentrated as some deep-tech categories, but it is still a power-law market. The typical company raised far less than the headline average suggests.

How much of the digital health funding signal is driven by outliers?

As of July 2026, outliers drove a large part of the digital health funding signal. Over the past 12 months, 8 deals above $50M represented 18.2% of deals but 53.0% of all disclosed capital.

Excluding rounds above $50M cuts total capital from $1.71B to $804.9M. That is the clearest sign that megarounds explain much of the apparent strength in the digital health market.

The largest rounds also shape the category story. eMed, Aidoc, Assort Health, Nourish, Cadence, Pomelo Care, Latent, and Artera collectively explain why virtual care, clinical workflow, patient engagement, and remote monitoring look so strong.

This does not make the market weak. It means the digital health market is best read as a barbell: many normal Series A rounds on one side, and a small group of scaled platforms on the other.

Is the digital health market broad with many targets, or narrow with few fundable companies?

As of July 2026, the digital health market looks moderately broad by company count, but narrower by funding quality. Over the past 12 months, the dataset includes 44 deals across 44 unique companies.

That one-deal-per-company pattern is important. It means the dataset is not dominated by repeat raises from the same few startups, unlike markets where the same companies keep reappearing.

However, the investable surface area is not evenly distributed. Clinical Workflow Software and Virtual Care Platforms together account for 29 of 44 deals, or 65.9% of all activity.

So the digital health market is broad at the company level, but narrow in terms of what investors clearly want. Capital is concentrating around healthcare infrastructure, care delivery, access, and workflow automation.

Is digital health mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the digital health market is mostly an early-stage formation market by deal count, but more balanced by dollars. Over the past 12 months, Seed, Series A, and Series B represented 35 deals and 58.2% of capital.

Series A dominates the market. It accounts for 29 deals, or 65.9% of all disclosed rounds, and $855.4M, or 50.0% of all capital.

Late-stage rounds still matter because they are much larger. Series C, Series D+, and Growth Equity represented only 9 deals, but they captured $715.5M, or 41.8% of total funding.

The right interpretation is that digital health investors are still funding new platforms, but they reserve the largest checks for companies with visible operational traction. We cover this funding-stage split in more detail in our deeper analysis of the digital health market.

Which categories attract the most investor attention in digital health?

As of July 2026, Clinical Workflow Software and Virtual Care Platforms attract the most investor attention in digital health. Over the past 12 months, they produced 29 of 44 disclosed deals and raised $1.14B combined.

Clinical Workflow Software leads by deal count, with 15 deals and $511.2M raised. This shows that investors are strongly focused on administrative automation, clinical operations, access workflows, and AI-enabled capacity relief.

Virtual Care Platforms lead by capital, with $624.2M raised across 14 deals. The category benefits from large rounds in GLP-1 care, metabolic care, maternity, pediatrics, neurology, and hospital-based virtual care.

Patient Engagement Tools rank third, with 6 deals and $292.7M. Their funding strength is strongest when engagement connects directly to access, communications, adherence, or operational bottlenecks.

Which categories attract disproportionately large checks in the digital health market?

As of July 2026, Patient Engagement Tools attract disproportionately large checks in the digital health market. Over the past 12 months, the category represented 13.6% of deals but 17.1% of capital, giving it a capital-share-to-deal-share ratio of 1.25.

Virtual Care Platforms also over-index on capital, with a ratio of 1.15. That makes sense because virtual care companies often combine software, clinicians, distribution, reimbursement access, and operational services.

Remote Monitoring Solutions sit close to parity, with 11.4% of deals and 10.8% of capital. Cadence’s $100M round helped the category, but the overall segment remains smaller than virtual care and workflow software.

Clinical Workflow Software under-indexes slightly, with a ratio of 0.88. This means the category has many fundable companies, but fewer very large checks relative to its deal count.

Which geographies matter most for fundraising in the digital health market?

As of July 2026, North America is by far the most important geography for fundraising in the digital health market. Over the past 12 months, it captured 39 of 44 deals and $1.48B of disclosed capital.

That equals 88.6% of deals and 86.3% of capital. The dataset is therefore overwhelmingly a North American market signal, especially for provider, payer, employer, and health-system software models.

The Middle East ranks second by capital, with $165M across 2 deals. But that figure is heavily shaped by Aidoc’s $150M round, so it should be read as company-specific rather than ecosystem-wide.

Asia-Pacific produced 2 deals and $49.5M, while Europe produced 1 deal and $20M. Latin America and Africa had no qualifying disclosed rounds in this sample.

For more context on the regional shape of this market, see our full market deck on digital health funding.

Is the digital health opportunity set broad or concentrated in one hub?

As of July 2026, the digital health opportunity set is highly concentrated in North America. Over the past 12 months, North America accounted for nearly nine out of every ten disclosed deals.

This does not mean digital health is only a North American market. It means this public funding dataset is dominated by North American companies, especially those selling into U.S. healthcare workflows.

The rest of the world is visible, but thin. The Middle East, Asia-Pacific, and Europe together produced only 5 deals and $234.5M in disclosed capital.

The practical reading is simple: use this dataset mainly as a North American digital health funding signal. Global extrapolation should be cautious because non-North American regions are underrepresented.

Is digital health a market of small experiments or scaled financings?

As of July 2026, digital health is a market of mid-sized and scaled financings, not tiny experiments. Over the past 12 months, no qualifying round was below $5M, and 28 of 44 deals were above $20M.

The largest bucket is $20M to $50M, with 20 deals. Another 16 deals fell between $5M and $20M, while 8 deals cleared $50M.

The median round size was $25.1M, which is a useful benchmark for the typical disclosed round. The average round size was higher, at $38.9M, because large rounds pulled the mean upward.

Only 3 deals were above $100M, or 6.8% of the dataset. So digital health has megarounds, but it is not a market where most disclosed financings are mega-scale.

If you want to benchmark new funding announcements against this size distribution, use our digital health market report.

Who are the investors that appear the most in digital health fundraising?

As of July 2026, General Catalyst and Andreessen Horowitz appear most often in digital health fundraising. Over the past 12 months, each appeared in 4 disclosed deals in the dataset.

The next group of repeat investors appears twice. That group includes Black Opal Ventures, B Capital, Transformation Capital, Plural, Pear VC, Bain Capital Ventures, Spark Capital, and Menlo Ventures.

This repeat-investor pattern matters, but it is not extreme. The market has visible specialist conviction, but it is not controlled by only one or two funds.

One caveat is important. Round announcements usually disclose total round size, not individual investor check size, so investor repetition is a participation signal rather than a precise dollars-committed ranking.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.